OverviewSuggest Edit

Beam Therapeutics is a biotechnology company that develops precision genetic medicines making edits to individual base pairs in the genetic code. The company works on technologies to generate a pipeline of precision genetic medicines that repair disease-causing point mutations, write in protective genetic variations, and modulate the expression or function of disease-causing genes.
TypePublic
Founded2017
HQBoston, MA, US
Websitebeamtx.com

Latest Updates

Employees (est.) (Sept 2019)112(+29%)
Job Openings51
Revenue (FY, 2020)$24 K
Share Price (Jun 2021)$85

Key People/Management at Beam Therapeutics

David R. Liu

David R. Liu

Co-Founder
J. Keith Joung

J. Keith Joung

Co-Founder
Feng Zhang

Feng Zhang

Co-Founder
John Evans

John Evans

Chief Executive Officer and Director
Giuseppe Ciaramella

Giuseppe Ciaramella

President & Chief Scientific Officer
Amy Simon

Amy Simon

Chief Medical Officer
Show more

Beam Therapeutics Office Locations

Beam Therapeutics has an office in Boston
Boston, MA, US (HQ)
208 Newbury St
Show all (1)

Beam Therapeutics Financials and Metrics

Beam Therapeutics Revenue

Beam Therapeutics's revenue was reported to be $24 k in FY, 2020
USD

Revenue (Q1, 2021)

6.0k

Net income (Q1, 2021)

(201.6m)

EBIT (Q1, 2021)

(200.4m)

Market capitalization (18-Jun-2021)

5.3b

Closing stock price (18-Jun-2021)

85.0

Cash (31-Mar-2021)

97.2m

EV

5.4b
Beam Therapeutics's current market capitalization is $5.3 b.
Annual
USDFY, 2017FY, 2018FY, 2020

Revenue

24.0k

General and administrative expense

2.0m11.9m29.6m

R&D expense

5.9m33.9m103.2m

Operating expense total

7.9m45.7m194.6m
Quarterly
USDQ1, 2020Q2, 2020Q1, 2021

Revenue

6.0k6.0k6.0k

General and administrative expense

6.8m6.9m10.3m

R&D expense

21.5m19.4m190.1m

Operating expense total

30.5m34.2m201.6m
Annual
USDFY, 2017FY, 2018FY, 2020

Cash

1.9m146.4m162.2m

Prepaid Expenses

8.7m

Current Assets

2.0m148.3m308.3m

PP&E

335.0k16.9m38.5m
Quarterly
USDQ2, 2019Q1, 2020Q2, 2020Q1, 2021

Cash

37.9m126.1m125.3m97.2m

Prepaid Expenses

6.2m6.9m11.1m

Current Assets

129.4m259.6m234.8m514.6m

PP&E

21.0m24.8m25.7m52.0m
Annual
USDFY, 2017FY, 2018FY, 2020

Net Income

(8.0m)(116.7m)(194.6m)

Depreciation and Amortization

11.0k650.0k4.7m

Accounts Payable

726.0k2.4m60.0k

Cash From Operating Activities

(2.7m)(20.3m)(95.7m)
Quarterly
USDQ2, 2018Q2, 2019Q1, 2020Q2, 2020Q1, 2021

Net Income

(20.4m)(31.5m)(30.5m)(64.7m)(201.6m)

Depreciation and Amortization

53.0k1.6m1.1m2.2m1.4m

Accounts Payable

2.1m1.5m(471.0k)(53.0k)(666.0k)

Cash From Operating Activities

(7.9m)(37.2m)(27.4m)(50.2m)(38.6m)
USDFY, 2017

Financial Leverage

-0.3 x
Show all financial metrics

Beam Therapeutics Operating Metrics

Oct, 2019

Patents Issued

1

Programs

12

Trademarks (US)

2
Show all operating metrics

Beam Therapeutics Acquisitions / Subsidiaries

Company NameDateDeal Size
Blink Therapeutics Inc.

Beam Therapeutics Environment, Social & Governance (ESG) Ratings

CSRHub ESG ratingPremium dataset

50-59

out of 100

CSRHub logo

Beam Therapeutics Online and Social Media Presence

Embed Graph

Beam Therapeutics News and Updates

Beam Therapeutics Cofounder And Crispr Scientist Publishes Research On New Sickle Cell Treatment In Mice

Each year more than 300,000 babies around the world, most of them Black, are diagnosed with the painful and life-threatening sickle cell disease.

Beam Therapeutics to Participate in the 2021 Jefferies Virtual Healthcare Conference

CAMBRIDGE, Mass., May 25, 2021 (GLOBE NEWSWIRE) -- Beam Therapeutics Inc. (Nasdaq: BEAM), a biotechnology company developing precision genetic medicines through base editing, today announced that John Evans, chief executive officer, will participate in a fireside chat during the 2021 Jefferies Vir…

Beam Therapeutics Presents LNP Formulation Data at ASGCT and Reports First Quarter 2021 Financial Results

Data from Beam’s Novel LNP-mRNA Formulation Demonstrates In Vivo Editing in Liver Cells of Non-human Primates Up to 52%

Thinking about buying stock in Nokia, BioCryst Pharmaceuticals, Beam Therapeutics, Altimmune, or Citius Pharmaceuticals?

NEW YORK, April 30, 2021 /PRNewswire/ -- InvestorsObserver issues critical PriceWatch Alerts for NOK, BCRX, BEAM, ALT, and CTXR. To see how InvestorsObserver's proprietary scoring system rates these stocks, view the InvestorsObserver's PriceWatch Alert by selecting the corresponding link....

Beam Therapeutics Publishes Data Highlighting Ability to Rationally Design Base Editors for Precise Editing

Data Published in The CRISPR Journal Describe Inlaid Base Editors (IBEs) that Enhance Editing Efficiency and Capability, an Advancement of the Company’s Pioneering Work in Developing Base Editors

Beam Therapeutics Announces Business and Pipeline Progress and Reports Fourth Quarter and Full Year 2020 Financial Results

Company On-track to Submit First IND with BEAM-101 in the Second Half of 2021
Show more

Beam Therapeutics Blogs

Beam Therapeutics Announces Oral and Poster Presentations at 24th American Society of Gene and Cell Therapy Annual Meeting

CAMBRIDGE, Mass., April 27, 2021 (GLOBE NEWSWIRE) -- Beam Therapeutics Inc. (Nasdaq: BEAM), a biotechnology company developing precision genetic medicines through base editing, today announced that the company will present data highlighting its proprietary base editing approach in several

The Boston Globe Names Beam Therapeutics a Top Place to Work for 2020

Magazine honors company for second year in a row CAMBRIDGE, Mass., Nov. 20, 2020 (GLOBE NEWSWIRE) -- Beam Therapeutics Inc. (Nasdaq: BEAM), a biotechnology company developing precision genetic medicines through base editing, today has been named one of the Top Places to Work in Massachusetts in the

Beam Therapeutics Promotes Giuseppe Ciaramella, Ph.D., to President and Chief Scientific Officer

CAMBRIDGE, Mass., January 24, 2020 — Beam Therapeutics, a biotechnology company developing precision genetic medicines through base editing, today announced the promotion of chief scientific... The post Beam Therapeutics Promotes Giuseppe Ciaramella, Ph.D., to President and Chief Scientific Officer …

Beam Therapeutics Presents Preclinical Data for Complementary Base Editing Approaches for Hemoglobinopathies at ASH 2019

HPFH program achieves in vivo proof of concept of long term engraftment with >90% base editing maintained after 16 weeks   Makassar program demonstrates... The post Beam Therapeutics Presents Preclinical Data for Complementary Base Editing Approaches for Hemoglobinopathies at ASH 2019 appeared fi…

Beam Therapeutics to Present New Preclinical Data on Base Editing Programs for Hemoglobinopathies at ASH 2019

CAMBRIDGE, Mass. – November 21, 2019 – Beam Therapeutics, a biotechnology company developing precision genetic medicines through base editing, today announced that it will... The post Beam Therapeutics to Present New Preclinical Data on Base Editing Programs for Hemoglobinopathies at ASH 2019 appear…

The 2019 Top Places to Work in Massachusetts

Beam Therapeutics among the Boston Globe’s Top Places to Work, “Top small employers in Massachusetts for 2019” category. The post The 2019 Top Places to Work in Massachusetts appeared first on Beam Therapeautics.
Show more

Beam Therapeutics Frequently Asked Questions

  • When was Beam Therapeutics founded?

    Beam Therapeutics was founded in 2017.

  • Who are Beam Therapeutics key executives?

    Beam Therapeutics's key executives are David R. Liu, J. Keith Joung and Feng Zhang.

  • How many employees does Beam Therapeutics have?

    Beam Therapeutics has 112 employees.

  • What is Beam Therapeutics revenue?

    Latest Beam Therapeutics annual revenue is $24 k.

  • What is Beam Therapeutics revenue per employee?

    Latest Beam Therapeutics revenue per employee is $214.

  • Who are Beam Therapeutics competitors?

    Competitors of Beam Therapeutics include NewStem, ImmunoGenes and Canopy Biosciences.

  • Where is Beam Therapeutics headquarters?

    Beam Therapeutics headquarters is located at 208 Newbury St, Boston.

  • Where are Beam Therapeutics offices?

    Beam Therapeutics has an office in Boston.

  • How many offices does Beam Therapeutics have?

    Beam Therapeutics has 1 office.